Biodesix, Inc. (NASDAQ:BDSX) Chairman John Patience Acquires 75,000 Shares

Biodesix, Inc. (NASDAQ:BDSX) Chairman John Patience bought 75,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The shares were bought at an average cost of $1.38 per share, for a total transaction of $103,500.00. Following the completion of the acquisition, the chairman now owns 2,153,298 shares of the company’s stock, valued at $2,971,551.24. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Biodesix Stock Performance

Shares of BDSX remained flat at $1.34 during trading hours on Wednesday. The company had a trading volume of 797,321 shares, compared to its average volume of 159,360. The company has a debt-to-equity ratio of 0.99, a quick ratio of 3.28 and a current ratio of 3.28. Biodesix, Inc. has a 52-week low of $1.15 and a 52-week high of $2.21. The firm has a market capitalization of $194.54 million, a P/E ratio of -3.40 and a beta of 1.22. The stock has a 50-day moving average price of $1.71 and a 200-day moving average price of $1.61.

Biodesix (NASDAQ:BDSX) last issued its quarterly earnings results on Friday, November 1st. The company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The firm had revenue of $18.15 million during the quarter, compared to analysts’ expectations of $18.45 million. Biodesix had a negative return on equity of 369.89% and a negative net margin of 66.84%. During the same period in the previous year, the business earned ($0.12) earnings per share. On average, research analysts expect that Biodesix, Inc. will post -0.36 earnings per share for the current year.

Institutional Trading of Biodesix

Several large investors have recently added to or reduced their stakes in the stock. AIGH Capital Management LLC grew its holdings in Biodesix by 74.0% in the 2nd quarter. AIGH Capital Management LLC now owns 5,779,812 shares of the company’s stock valued at $8,843,000 after buying an additional 2,458,727 shares in the last quarter. Perceptive Advisors LLC acquired a new position in shares of Biodesix in the 2nd quarter valued at $3,326,000. Farallon Capital Management LLC acquired a new position in shares of Biodesix in the 2nd quarter valued at $2,874,000. Essex Investment Management Co. LLC lifted its stake in shares of Biodesix by 1.4% in the 1st quarter. Essex Investment Management Co. LLC now owns 925,614 shares of the company’s stock valued at $1,324,000 after purchasing an additional 12,669 shares during the last quarter. Finally, Perkins Capital Management Inc. lifted its stake in shares of Biodesix by 74.7% in the 3rd quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock valued at $1,290,000 after purchasing an additional 310,000 shares during the last quarter. 20.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Craig Hallum assumed coverage on Biodesix in a research report on Friday, July 26th. They set a “buy” rating and a $3.00 price target on the stock. Scotiabank assumed coverage on Biodesix in a research report on Monday, September 16th. They set a “sector outperform” rating and a $3.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Biodesix currently has an average rating of “Buy” and an average price target of $3.06.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.